Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Turning Point Therapeutics, Inc. announced that TPX-0022, the company’s inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R, has been granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with gastric cancer, including gastroesophageal junction adenocarcinoma.